Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 12/2014

01.08.2014 | R&D Insight Report

Nemonoxacin: First Global Approval

verfasst von: Raewyn M. Poole

Erschienen in: Drugs | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Nemonoxacin (Taigexyn®), a non-fluorinated quinolone antibacterial agent, is under development with TaiGen Biotechnology for the oral and intravenous treatment of community-acquired pneumonia (CAP) and the oral treatment of diabetic foot ulcer infections and skin and soft tissue infections. Oral nemonoxacin has been approved in Taiwan for the treatment of CAP in adults. This article summarizes the milestones in the development of nemonoxacin leading to this first approval for the treatment of CAP.
Literatur
1.
Peto L, Nadjm B, Horby P, et al. The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review. Trans R Soc Trop Med Hyg. 2014;108(6):326–37.PubMedCentralPubMedCrossRef
2.
Song JH, Thamlikitkul V, Hsueh PR. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents. 2011;38(2):108–17.PubMed
3.
Lai CC, Lee KY, Lin SW, et al. Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia. Expert Rev Anti Infect Ther. 2014;12(4):401–17.PubMedCrossRef
4.
Goyet S, Vlieghe E, Kumar V, et al. Etiologies and resistance profiles of bacterial community-acquired pneumonia in Cambodian and neighboring countries’ health care settings: a systematic review (1995 to 2012). PLoS One. 2014;9(3):e89637.PubMedCentralPubMedCrossRef
5.
Torres A, Blasi F, Peetermans WE, et al. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis. 2014;33(7):1065–79.PubMedCentralPubMedCrossRef
6.
Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72.PubMedCrossRef
7.
Bush K. Improving known classes of antibiotics: an optimistic approach for the future. Curr Opin Pharmacol. 2012;12(5):527–34.PubMedCrossRef
8.
Chotikanatis K, Kohlhoff SA, Hammerschlag MR. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 2014;58(3):1800–1.PubMedCrossRef
9.
Chen Y-H, Liu C-Y, Lu J-J, et al. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. J Antimicrob Chemother. 2009;64(6):1226–9.PubMedCrossRef
10.
11.
TaiGen Biotechnology Co Ltd. TaiGen Biotechnology announces submission of new drug application for nemonoxacin in Taiwan and Mainland China [media release]; 16 May 2013. http://​www.​taigenbiotech.​com.
12.
TaiGen Biotechnology Co Ltd. TaiGen Biotechnology receives Qualified Infectious Disease Product and Fast Track designations from the U.S. Food and Drug Administration for nemonoxacin (Taigexyn(Rm)) [media release]; 23 Dec 2013. http://​www.​taigenbiotech.​com.​tw.
13.
14.
TaiGen Biotechnology Co Ltd. TaiGen amends global license agreement with Warner Chilcott plc for development and commercialization of nemonoxacin—a new generation quinolone antibiotic [media release]; 14 Oct 2010. http://​www.​taigenbiotech.​com.
15.
16.
17.
18.
Lauderdale T-L, Shiau Y-R, Lai J-F, et al. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob Agents Chemother. 2010;54(3):1338–42.PubMedCentralPubMedCrossRef
19.
Adam HJ, Laing NM, King CR, et al. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother. 2009;53(11):4915–20.PubMedCentralPubMedCrossRef
20.
Lai C-C, Tan C-K, Lin SH, et al. Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species. J Antimicrob Chemother. 2009;64(1):73–8.PubMedCrossRef
21.
Lai C-C, Liu W-L, Ko W-C, et al. Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species. Antimicrob Agents Chemother. 2011;55(5):2084–91.PubMedCentralPubMedCrossRef
22.
Tan C-K, Lai C-C, Liao C-H, et al. Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother. 2009;64(2):428–9.PubMedCrossRef
23.
Liao CH, Ko WC, Lu JJ, et al. Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan. Antimicrob Agents Chemother. 2012;56(7):3943–9.PubMedCentralPubMedCrossRef
24.
Lin YC, Huang YT, Tsai PJ, et al. Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in Taiwan. Antimicrob Agents Chemother. 2011;55(4):1701–5.PubMedCentralPubMedCrossRef
25.
Liang W, Chen Y-C, Cao Y-R, et al. Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model. Antimicrob Agents Chemother. 2013;57(7):2942–7.PubMedCentralPubMedCrossRef
26.
King C, Lin L, Leunk R, et al. In vitro resistance development to nemonoxacin for Streptococcus pneumoniae [abstract no. C1-1971]. In: 46th Infectious Diseases Society of America (IDSA) Annual Meeting; 25–28 Oct 2008; Washington, DC, USA.
27.
Li C-R, Li Y, Li G-Q, et al. In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone. J Antimicrob Chemother. 2010;65(11):2411–5.PubMedCrossRef
28.
Lin L, Chang L-W, Tsai C-Y, et al. Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):405–10.PubMedCentralPubMedCrossRef
29.
Chung DT, Tsai C-Y, Chen S-J, et al. Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):411–7.PubMedCentralPubMedCrossRef
30.
Guo B, Wu X, Zhang Y, et al. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses. Clin Drug Investig. 2012;32(7):475–86.PubMedCrossRef
31.
TaiGen Biotechnology Co Ltd. Study to evaluate the efficacy and safety of oral administration with nemonoxacin and levofloxacin in patients with CAP [ClinicalTrials.gov identifier NCT01529476] US National Institutes of Health, ClinicalTrials.gov. 2012. http://​clinicaltrials.​gov/​show/​NCT01529476. Accessed 2 July 2014.
32.
van Rensburg DJJ, Perng R-P, Mitha IH, et al. Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. Antimicrob Agents Chemother. 2010;54(10):4098–106.PubMedCentralPubMedCrossRef
33.
Lipsky BA, Gani M, Rogers L, et al. Nemonoxacin for treating diabetic foot infections: an open-label, single-arm, multiple-center study [abstract no. L1-344]. In: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12–15 Sept 2010; Boston, MA, USA.
34.
Metadaten
Titel
Nemonoxacin: First Global Approval
verfasst von
Raewyn M. Poole
Publikationsdatum
01.08.2014
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 12/2014
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-014-0270-0

Weitere Artikel der Ausgabe 12/2014

Drugs 12/2014 Zur Ausgabe

Therapy in Practice

Functional Esophageal Disorders: Pharmacological Options

Adis Drug Evaluation

Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases

Leading Article

New Therapies for Hepatitis C: Considerations in Patients with Renal Impairment

Therapy in Practice

Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections

Erratum

Erratum to: Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor

Adis Drug Evaluation

Tafamidis: A Review of Its Use in Familial Amyloid Polyneuropathy